Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of Attention Deficit Hyperactivity Disorder medication in (a) Shropshire and (b) England.

Disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD) have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Information on the adequacy of the availability of ADHD medication is not collected at local level.

The Department has been working with industry to help resolve those issues and expedite deliveries, to boost supplies of these important medicines as quickly as possible. As a result of our ongoing activity and intensive work, some issues have been resolved. Certain strengths of lisdexamphetamine, guanfacine, and all strengths of atomoxetine capsules are now available.

Unfortunately, some medicine supply issues remain for some strengths of lisdexamphetamine and methylphenidate. We are escalating these issues within the manufacturers to ensure action is taken to resolve them as quickly as possible. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.